P Veronesi
Overview
Explore the profile of P Veronesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
2314
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peradze N, Polizzi A, Pagan E, Bottazzoli E, Bagnardi V, Sangalli C, et al.
Eur J Surg Oncol
. 2025 Feb;
51(6):109714.
PMID: 40020278
Introduction: Pleomorphic lobular carcinoma (PLC) is a rare variant of invasive lobular carcinoma of the breast (ILC) and few studies have reported controversial data regarding its outcomes. The information provided...
2.
Filippone M, Gaglio D, Bonfanti R, Tucci F, Ceccacci E, Pennisi R, et al.
Nat Commun
. 2022 May;
13(1):2642.
PMID: 35550508
Cyclin-dependent kinase 12 (CDK12) overexpression is implicated in breast cancer, but whether it has a primary or only a cooperative tumorigenic role is unclear. Here, we show that transgenic CDK12...
3.
Montagna E, Bellerba F, Sangalli C, Gandini S, Cancello G, Trillo Aliaga P, et al.
Eur J Surg Oncol
. 2021 Jun;
47(10):2694-2695.
PMID: 34116901
No abstract available.
4.
Dicuonzo S, Leonardi M, Raimondi S, Corrao G, Bagnardi V, Gerardi M, et al.
Clin Transl Oncol
. 2021 Feb;
23(7):1415-1428.
PMID: 33537865
Aims: To report toxicity of a hypofractionated scheme of whole-breast (WB) intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) to the tumor bed (TB) using Tomotherapy with Direct modality. Methods:...
5.
Montagna E, Pagan E, Bagnardi V, Colleoni M, Cancello G, Munzone E, et al.
Breast Cancer Res Treat
. 2020 Sep;
184(3):783-795.
PMID: 32929568
Purpose: The development of the adjuvant therapy requires that clinicians and patients should discuss the magnitude of benefit of treatment for individual patient, estimating the pros and cons and the...
6.
Magnoni F, Colleoni M, Mattar D, Corso G, Bagnardi V, Frassoni S, et al.
Ann Surg Oncol
. 2020 May;
27(11):4488-4499.
PMID: 32436193
Background: Contralateral axillary lymph node metastasis (CAM) is an infrequent clinical condition currently considered an M1, stage IV, disease. Due to the absence of shared data on CAM significance and...
7.
Gelber R, Coates A, Gelber S, Orecchia R, Veronesi P, Di Leo A, et al.
Ann Oncol
. 2020 Mar;
31(6):671-673.
PMID: 32217075
No abstract available.
8.
De Lorenzi F, Corso G, Botta F, Invento A, Marchetti A, Sala P, et al.
Eur J Surg Oncol
. 2020 Jan;
46(6):1013-1020.
PMID: 31955994
Background: Ipsilateral breast cancer recurrence (IBTR) occurs in about 7% of patients with primary invasive breast tumor. Salvage mastectomy and breast reconstruction are often discussed and latissimus dorsi (LD) flap...
9.
Veronesi P, Corso G
Breast
. 2019 Dec;
48 Suppl 1:S53-S56.
PMID: 31839161
Axillary management in breast cancer is still controversial. Recent clinical trials have clearly demonstrated that in breast-conserving surgery, axillary dissection could be an overtreatment when metastases are present in only...
10.
Corso G, Galimberti V, Veronesi P
Clin Transl Oncol
. 2019 May;
22(3):445-446.
PMID: 31073973
No abstract available.